Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

about

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Item

http://www.wikidata.org/entity/Q35755674

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Lack of a significant pharmaco ...... in allogeneic HSCT recipients.

@ast

Lack of a significant pharmaco ...... in allogeneic HSCT recipients.

@en

type

Item

label

Lack of a significant pharmaco ...... in allogeneic HSCT recipients.

@ast

Lack of a significant pharmaco ...... in allogeneic HSCT recipients.

@en

prefLabel

Lack of a significant pharmaco ...... in allogeneic HSCT recipients.

@ast

Lack of a significant pharmaco ...... in allogeneic HSCT recipients.

@en

P1476

Lack of a significant pharmaco ...... in allogeneic HSCT recipients

@en

P2093

Alex Ganetsky

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

Ran Reshef

http://www.w3.org/2001/XMLSchema#string

Robert H Vonderheide

http://www.w3.org/2001/XMLSchema#string

Todd A Miano

http://www.w3.org/2001/XMLSchema#string

P2860

Current and emerging strategies for the prevention of graft-versus-host disease

Long-term effect of hospital pay for performance on mortality in England

Random-effects models for longitudinal data

Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Maraviroc for previously treated patients with R5 HIV-1 infection

Dendritic cells, chemokine receptors and autoimmune inflammatory diseases.

Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis

Pharmacokinetic principles of immunosuppressive drugs.

P304

2078-2083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKV082

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mitchell Hughes

P577

2015-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25881619

http://www.w3.org/2001/XMLSchema#string

P932

4472330

http://www.w3.org/2001/XMLSchema#string